-
Innovation Ranking
NewInnovation Ranking – Chimerix Inc
Chimerix Inc (Chimerix) is a biopharmaceutical company. It develops, discovers, and commercializes novel and oral antiviral therapeutics. The company’s pipeline product portfolio includes ONC201, ONC206, ONC212, CMX521 drug candidates. Its products are used to treat various diseases like gliomas, central nervous system tumors, SARS-CoV-2 (COVID-19), and IND-enabling studies. Its brincidofovir tablet and oral suspension formulations are used in the treatment of smallpox disease in adult and pediatric patients. The company markets its products under the brand name of TEMBEXA. The...
-
Product Insights
NewNet Present Value Model: Chimerix Inc’s Dordaviprone
Empower your strategies with our Net Present Value Model: Chimerix Inc's Dordaviprone report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Chimerix Inc’s ONC-201
Empower your strategies with our Net Present Value Model: Chimerix Inc's ONC-201 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Chimerix Inc’s Dociparstat Sodium
Empower your strategies with our Net Present Value Model: Chimerix Inc's Dociparstat Sodium report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Chimerix Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Chimerix Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AL-8326 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AL-8326 in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AL-8326 in Small-Cell Lung Cancer Drug Details: AL-8326 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dordaviprone Hydrochloride in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dordaviprone Hydrochloride in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dordaviprone Hydrochloride in Acute Lymphocytic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dordaviprone Hydrochloride in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dordaviprone Hydrochloride in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dordaviprone Hydrochloride in Refractory Acute Myeloid Leukemia Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dordaviprone Hydrochloride in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dordaviprone Hydrochloride in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dordaviprone Hydrochloride in Relapsed Acute Myeloid Leukemia Drug...
-
Product Insights
Paraganglioma (Glomus Jugulare Tumor) – Drugs In Development, 2023
Global Markets Direct’s, ‘Paraganglioma (Glomus Jugulare Tumor) - Drugs In Development, 2023’, provides an overview of the Paraganglioma (Glomus Jugulare Tumor) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Paraganglioma (Glomus Jugulare Tumor), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...